china

china

Pasadena-based Arrowhead Pharmaceuticals has landed a $60 million investment from Silicon Valley health care venture firm Vivo Capital to launch a new joint venture tapping into one of the fastest-growing markets for drugs: China.

On Monday, the local pharma firm announced that it is partnering with Vivo to form Visirna Therapeutics, a new venture that aims to develop and sell four of Arrowhead’s early-stage treatments in mainland China, Hong Kong, Macau and Taiwan. Arrowhead’s therapies utilize RNA interference—a new way to manipulate genes in cells that has largely been used to treat cardiometabolic diseases like hypertension, hyperlipidemia and type 2 diabetes.

Read more Show less

Faraday Future named former Jaguar Land Rover executive Xuefeng "Chris" Chen as the chief executive of its China division as the company prepares to enter the world's largest electric vehicle market and develop its binational market strategy.

With a new Chinese investor, Faraday is focused on developing its market in China, which is over triple the size of the U.S. market, according to a 2019 report by the International Energy Agency.

Read more Show less
Trending